Literature DB >> 31969384

TRPV4 Protects the Lung from Bacterial Pneumonia via MAPK Molecular Pathway Switching.

Rachel G Scheraga1,2, Susamma Abraham2, Lisa M Grove2, Brian D Southern3,2, James F Crish2, Apostolos Perelas3, Christine McDonald2, Kewal Asosingh2, Jeffrey D Hasday4, Mitchell A Olman1,2.   

Abstract

Mechanical cell-matrix interactions can drive the innate immune responses to infection; however, the molecular underpinnings of these responses remain elusive. This study was undertaken to understand the molecular mechanism by which the mechanosensitive cation channel, transient receptor potential vanilloid 4 (TRPV4), alters the in vivo response to lung infection. For the first time, to our knowledge, we show that TRPV4 protects the lung from injury upon intratracheal Pseudomonas aeruginosa in mice. TRPV4 functions to enhance macrophage bacterial clearance and downregulate proinflammatory cytokine secretion. TRPV4 mediates these effects through a novel mechanism of molecular switching of LPS signaling from predominant activation of the MAPK, JNK, to that of p38. This is accomplished through the activation of the master regulator of inflammation, dual-specificity phosphatase 1. Further, TRPV4's modulation of the LPS signal is mechanosensitive in that both upstream activation of p38 and its downstream biological consequences depend on pathophysiological range extracellular matrix stiffness. We further show the importance of TRPV4 on LPS-induced activation of macrophages from healthy human controls. These data are the first, to our knowledge, to demonstrate new roles for macrophage TRPV4 in regulating innate immunity in a mechanosensitive manner through the modulation of dual-specificity phosphatase 1 expression to mediate MAPK activation switching.
Copyright © 2020 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 31969384      PMCID: PMC7033031          DOI: 10.4049/jimmunol.1901033

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  71 in total

1.  p38 Mitogen-activated protein kinase-, calcium-calmodulin-dependent protein kinase-, and calcineurin-mediated signaling pathways transcriptionally regulate myogenin expression.

Authors:  Qing Xu; Lu Yu; Lanying Liu; Ching Fung Cheung; Xue Li; Siu-Pok Yee; Xiang-Jiao Yang; Zhenguo Wu
Journal:  Mol Biol Cell       Date:  2002-06       Impact factor: 4.138

2.  The kinase p38 alpha serves cell type-specific inflammatory functions in skin injury and coordinates pro- and anti-inflammatory gene expression.

Authors:  Chun Kim; Yasuyo Sano; Kristina Todorova; Bradley A Carlson; Luis Arpa; Antonio Celada; Toby Lawrence; Kinya Otsu; Janice L Brissette; J Simon C Arthur; Jin Mo Park
Journal:  Nat Immunol       Date:  2008-09       Impact factor: 25.606

3.  FAK-related nonkinase is a multifunctional negative regulator of pulmonary fibrosis.

Authors:  Qiang Ding; Guo-Qiang Cai; Meng Hu; Youfeng Yang; Anni Zheng; Qinjiu Tang; Candece L Gladson; Haurko Hayasaka; Hongju Wu; Zhiying You; Brian D Southern; Lisa M Grove; S Ohidar Rahaman; Haotian Fang; Mitchell A Olman
Journal:  Am J Pathol       Date:  2013-03-14       Impact factor: 4.307

4.  A mouse model of chronic pulmonary infection with Pseudomonas aeruginosa and Pseudomonas cepacia.

Authors:  J R Starke; M S Edwards; C Langston; C J Baker
Journal:  Pediatr Res       Date:  1987-12       Impact factor: 3.756

5.  A MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cells.

Authors:  J Han; J D Lee; L Bibbs; R J Ulevitch
Journal:  Science       Date:  1994-08-05       Impact factor: 47.728

6.  TRPV4 inhibition counteracts edema and inflammation and improves pulmonary function and oxygen saturation in chemically induced acute lung injury.

Authors:  Shrilatha Balakrishna; Weifeng Song; Satyanarayana Achanta; Stephen F Doran; Boyi Liu; Melanie M Kaelberer; Zhihong Yu; Aiwei Sui; Mui Cheung; Emma Leishman; Hilary S Eidam; Guosen Ye; Robert N Willette; Kevin S Thorneloe; Heather B Bradshaw; Sadis Matalon; Sven-Eric Jordt
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2014-05-16       Impact factor: 5.464

7.  Pulmonary macrophage transplantation therapy.

Authors:  Takuji Suzuki; Paritha Arumugam; Takuro Sakagami; Nico Lachmann; Claudia Chalk; Anthony Sallese; Shuichi Abe; Cole Trapnell; Brenna Carey; Thomas Moritz; Punam Malik; Carolyn Lutzko; Robert E Wood; Bruce C Trapnell
Journal:  Nature       Date:  2014-10-01       Impact factor: 49.962

Review 8.  TRPV4: Molecular Conductor of a Diverse Orchestra.

Authors:  John P M White; Mario Cibelli; Laszlo Urban; Bernd Nilius; J Graham McGeown; Istvan Nagy
Journal:  Physiol Rev       Date:  2016-07       Impact factor: 37.312

9.  Frontline Science: Anti-PD-L1 protects against infection with common bacterial pathogens after burn injury.

Authors:  Naeem K Patil; Liming Luan; Julia K Bohannon; Antonio Hernandez; Yin Guo; Edward R Sherwood
Journal:  J Leukoc Biol       Date:  2017-12-21       Impact factor: 6.011

10.  TRPV4 activation triggers protective responses to bacterial lipopolysaccharides in airway epithelial cells.

Authors:  Yeranddy A Alpizar; Brett Boonen; Alicia Sanchez; Carole Jung; Alejandro López-Requena; Robbe Naert; Brecht Steelant; Katrien Luyts; Cristina Plata; Vanessa De Vooght; Jeroen A J Vanoirbeek; Victor M Meseguer; Thomas Voets; Julio L Alvarez; Peter W Hellings; Peter H M Hoet; Benoit Nemery; Miguel A Valverde; Karel Talavera
Journal:  Nat Commun       Date:  2017-10-20       Impact factor: 14.919

View more
  15 in total

1.  COVID-19: Urgent Reconsideration of Lung Edema as a Preventable Outcome: Inhibition of TRPV4 As a Promising and Feasible Approach.

Authors:  Wolfgang Kuebler; Sven-Eric Jordt; Wolfgang Liedtke
Journal:  SSRN       Date:  2020-03-23

Review 2.  Role of the purinergic signaling network in lung ischemia-reperfusion injury.

Authors:  Nathan Haywood; Huy Q Ta; Evan Rotar; Zdravka Daneva; Swapnil K Sonkusare; Victor E Laubach
Journal:  Curr Opin Organ Transplant       Date:  2021-04-01       Impact factor: 2.269

3.  Piezo1-mediated stellate cell activation causes pressure-induced pancreatic fibrosis in mice.

Authors:  Sandip M Swain; Joelle M-J Romac; Steven R Vigna; Rodger A Liddle
Journal:  JCI Insight       Date:  2022-04-22

4.  Urgent reconsideration of lung edema as a preventable outcome in COVID-19: inhibition of TRPV4 represents a promising and feasible approach.

Authors:  Wolfgang M Kuebler; Sven-Eric Jordt; Wolfgang B Liedtke
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2020-05-13       Impact factor: 5.464

Review 5.  Mechanobiological Principles Influence the Immune Response in Regeneration: Implications for Bone Healing.

Authors:  Raphael S Knecht; Christian H Bucher; Sophie Van Linthout; Carsten Tschöpe; Katharina Schmidt-Bleek; Georg N Duda
Journal:  Front Bioeng Biotechnol       Date:  2021-02-12

6.  The Roles of Transient Receptor Potential Vanilloid 1 and 4 in Pneumococcal Nasal Colonization and Subsequent Development of Invasive Disease.

Authors:  Masamitsu Kono; Denisa Nanushaj; Hideki Sakatani; Daichi Murakami; Masayoshi Hijiya; Tetsuya Kinoshita; Tatsuya Shiga; Fumie Kaneko; Keisuke Enomoto; Gen Sugita; Masayasu Miyajima; Yuka Okada; Shizuya Saika; Muneki Hotomi
Journal:  Front Immunol       Date:  2021-11-03       Impact factor: 7.561

Review 7.  The Role of TRPV4 in Regulating Innate Immune Cell Function in Lung Inflammation.

Authors:  Rachel G Scheraga; Brian D Southern; Lisa M Grove; Mitchell A Olman
Journal:  Front Immunol       Date:  2020-06-26       Impact factor: 7.561

Review 8.  TRPV4: A Physio and Pathophysiologically Significant Ion Channel.

Authors:  Tamara Rosenbaum; Miguel Benítez-Angeles; Raúl Sánchez-Hernández; Sara Luz Morales-Lázaro; Marcia Hiriart; Luis Eduardo Morales-Buenrostro; Francisco Torres-Quiroz
Journal:  Int J Mol Sci       Date:  2020-05-28       Impact factor: 5.923

Review 9.  TRPV4-A Missing Link Between Mechanosensation and Immunity.

Authors:  Laura Michalick; Wolfgang M Kuebler
Journal:  Front Immunol       Date:  2020-03-10       Impact factor: 7.561

10.  Emerging pharmacological therapies for ARDS: COVID-19 and beyond.

Authors:  Shahd Horie; Bairbre McNicholas; Emanuele Rezoagli; Tài Pham; Ger Curley; Danny McAuley; Cecilia O'Kane; Alistair Nichol; Claudia Dos Santos; Patricia R M Rocco; Giacomo Bellani; John G Laffey
Journal:  Intensive Care Med       Date:  2020-07-11       Impact factor: 41.787

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.